Table 1. Patients’ baseline characteristics.

Variables	t-MNs (−)	t-MNs (+)	Total
Patient number	48	4	52
Age at OC or PPC (years)	57 [37–77]	45 [42–53]	56 [37–77]
Presence of germline BRCA 1/2 (+) mutation	28 (58.3)	4 (100.0)	32 (61.5)
Diagnosed other cancer	7 (14.6)	2 (50.0)	9 (17.3)
Cancer type
OC	44 (91.7)	4 (100.0)	48 (92.3)
PPC	4 (8.3)	0 (0.0)	4 (7.7)
OC or PPC stage	45	4	49
II	1 (2.2)	0 (0.0)	1 (2.0)
III	37 (82.2)	1 (25.0)	38 (77.6)
IV	7 (15.5)	3 (75.0)	10 (20.4)
Median number of chemotherapy agent	4	7	5
Radiotherapy	10 (20.8)	4 (100.0)	14 (26.9)
G-CSF application	26 (54.1)	4 (100.0)	30 (57.7)
Type of PARPi
Olaparib	21 (43.8)	4 (100.0)	25 (48.1)
Niraparib	27 (56.3)	0 (0.0)	27 (51.9)
Reasons for quitting PARPi
Progression of cancer	24 (50.0)	4 (100.0)	28 (53.8)
Side effect	2 (4.2)	0 (0.0)	2 (3.8)
Ends after maintenance therapy period	6 (12.5)	0 (0.0)	6 (11.5)
Other cause	6 (12.5)	0 (0.0)	6 (11.5)
Ongoing	10 (20.8)	0 (0.0)	10 (19.2)
PARPi usage period (months)	13.4 [0.2–68.2]	16.3 [6.2–48.8]	14.2 [0.2–68.2]
OS from OC diagnosis (years)	4.8 [1.2–20.9]	13.4 [8.1–17.6]	5.2 [1.2–20.9]

Data are presented as number, median [range], or n (%), unless otherwise stated. t-MNs, therapy-related myeloid neoplasms; OC, ovarian cancer; PPC, primary peritoneal cancer; BRCA, breast cancer gene; G-CSF, granulocyte colony stimulating factor; PARPi, poly(ADP-ribose) polymerase inhibitor; OS, overall survival.